The latest announcement is out from BioNxt Solutions ( (TSE:BNXT) ).
BioNxt Solutions Inc. has successfully closed the final tranche of its non-brokered private placement of convertible debenture units, raising a total of $2.5 million. The funds will be used for product development, intellectual property filings, debt repayment, and general working capital, supporting the company’s strategic focus on advancing its drug delivery technologies and expanding its market presence.
More about BioNxt Solutions
BioNxt Solutions Inc. is a bioscience innovator specializing in next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The company focuses on therapeutic areas such as autoimmune diseases, neurological disorders, and longevity, with proprietary platforms including Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets). BioNxt operates research and development in North America and Europe, targeting European markets for regulatory approvals and commercialization.
YTD Price Performance: 34.39%
Average Trading Volume: 9,645
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $44.97M
See more data about BNXT stock on TipRanks’ Stock Analysis page.